# Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients

> **NCT01226537** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hamad Medical Corporation** · enrollment: 20 (estimated)

## Conditions studied

- it is a Group of Metabolic Diseases in
- Which a Person Has High Blood Sugar, Either
- Because the Body Does Not Produce Enough Insulin,
- or Because Cells do Not Respond to the Insulin That
- is Produced.

## Interventions

- **DRUG:** Taurine

## Key facts

- **NCT ID:** NCT01226537
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-11
- **Primary completion:** 2013-11
- **Final completion:** 2014-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2012-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01226537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01226537, "Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01226537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*